Gergő Berke1, Noémi Gede1, Letícia Szadai2, Klementina Ocskay1, Péter Hegyi1,3,4, Miklós Sahin-Tóth5, Eszter Hegyi1. 1. Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary. 2. Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. 3. Centre for Translational Medicine, Semmelweis University, Budapest, Hungary. 4. Division of Pancreatic Diseases, Heart and Vascular Centre, Semmelweis University, Budapest, Hungary. 5. Department of Surgery, University of California, Los Angeles, Los Angeles, California, United States of America.
Abstract
INTRODUCTION: Cystic fibrosis transmembrane conductance regulator (CFTR) plays a central role in pancreatic ductal fluid secretion by mediating Cl- and HCO3- ion transport across the apical membrane. Severe CFTR mutations that diminish chloride conductance cause cystic fibrosis (CF) if both alleles are affected, whereas heterozygous carrier status increases risk for chronic pancreatitis (CP). It has been proposed that a subset of CFTR variants characterized by a selective bicarbonate conductance defect (CFTRBD) may be associated with CP but not CF. However, a rigorous genetic analysis of the presumed association has been lacking. AIMS: To investigate the role of heterozygous CFTRBD variants in CP by meta-analysis of published case-control studies. MATERIALS AND METHODS: A systematic search was conducted in the MEDLINE, Embase, Scopus, and CENTRAL databases for published studies that reported the CFTRBD variants p.R74Q, p.R75Q, p.R117H, p.R170H, p.L967S, p.L997F, p.D1152H, p.S1235R, and p.D1270N in CP patients and controls. RESULTS: Twenty-two studies were eligible for quantitative synthesis. Combined analysis of the 9 CFTRBD variants indicated enrichment in CP patients versus controls (OR = 2.31, 95% CI = 1.17-4.56). Individual analysis of CFTRBD variants revealed no association of p.R75Q with CP (OR = 1.12, 95% CI = 0.89-1.40), whereas variants p.R117H and p.L967S were significantly overrepresented in cases relative to controls (OR = 3.16, 95% CI = 1.94-5.14, and OR = 3.88, 95% CI = 1.32-11.47, respectively). The remaining 6 low-frequency variants gave inconclusive results when analyzed individually, however, their pooled analysis indicated association with CP (OR = 2.08, 95% CI = 1.38-3.13). CONCLUSION: Heterozygous CFTRBD variants, with the exception of p.R75Q, increase CP risk about 2-4-fold.
INTRODUCTION: Cystic fibrosis transmembrane conductance regulator (CFTR) plays a central role in pancreatic ductal fluid secretion by mediating Cl- and HCO3- ion transport across the apical membrane. Severe CFTR mutations that diminish chloride conductance cause cystic fibrosis (CF) if both alleles are affected, whereas heterozygous carrier status increases risk for chronic pancreatitis (CP). It has been proposed that a subset of CFTR variants characterized by a selective bicarbonate conductance defect (CFTRBD) may be associated with CP but not CF. However, a rigorous genetic analysis of the presumed association has been lacking. AIMS: To investigate the role of heterozygous CFTRBD variants in CP by meta-analysis of published case-control studies. MATERIALS AND METHODS: A systematic search was conducted in the MEDLINE, Embase, Scopus, and CENTRAL databases for published studies that reported the CFTRBD variants p.R74Q, p.R75Q, p.R117H, p.R170H, p.L967S, p.L997F, p.D1152H, p.S1235R, and p.D1270N in CP patients and controls. RESULTS: Twenty-two studies were eligible for quantitative synthesis. Combined analysis of the 9 CFTRBD variants indicated enrichment in CP patients versus controls (OR = 2.31, 95% CI = 1.17-4.56). Individual analysis of CFTRBD variants revealed no association of p.R75Q with CP (OR = 1.12, 95% CI = 0.89-1.40), whereas variants p.R117H and p.L967S were significantly overrepresented in cases relative to controls (OR = 3.16, 95% CI = 1.94-5.14, and OR = 3.88, 95% CI = 1.32-11.47, respectively). The remaining 6 low-frequency variants gave inconclusive results when analyzed individually, however, their pooled analysis indicated association with CP (OR = 2.08, 95% CI = 1.38-3.13). CONCLUSION: Heterozygous CFTRBD variants, with the exception of p.R75Q, increase CP risk about 2-4-fold.
Authors: M Tzetis; M Kaliakatsos; M Fotoulaki; A Papatheodorou; S Doudounakis; A Tsezou; P Makrythanasis; E Kanavakis; S Nousia-Arvanitakis Journal: Clin Genet Date: 2007-05 Impact factor: 4.438
Authors: Jorg Kleeff; David C Whitcomb; Tooru Shimosegawa; Irene Esposito; Markus M Lerch; Thomas Gress; Julia Mayerle; Asbjørn Mohr Drewes; Vinciane Rebours; Fatih Akisik; J Enrique Domínguez Muñoz; John P Neoptolemos Journal: Nat Rev Dis Primers Date: 2017-09-07 Impact factor: 52.329
Authors: Hazel M Ní Chonchubhair; Sinead N Duggan; Suzanne M Egan; Marcus Kenyon; Dermot O'Toole; Ross McManus; Kevin C Conlon Journal: HPB (Oxford) Date: 2020-07-12 Impact factor: 3.647
Authors: Jessica LaRusch; Jinsei Jung; Ignacio J General; Michele D Lewis; Hyun Woo Park; Randall E Brand; Andres Gelrud; Michelle A Anderson; Peter A Banks; Darwin Conwell; Christopher Lawrence; Joseph Romagnuolo; John Baillie; Samer Alkaade; Gregory Cote; Timothy B Gardner; Stephen T Amann; Adam Slivka; Bimaljit Sandhu; Amy Aloe; Michelle L Kienholz; Dhiraj Yadav; M Michael Barmada; Ivet Bahar; Min Goo Lee; David C Whitcomb Journal: PLoS Genet Date: 2014-07-17 Impact factor: 5.917